Back to Results
First PageMeta Content



KEI request for investigation into anticompetitive aspects of Gilead Voluntary Licenses for patents on Tenofivir and Emtricitabine 12 February 2007 Federal Trade Commission Washington, DC Attn: Randy Marks
Add to Reading List

Document Date: 2017-11-20 13:59:46

Open Document

File Size: 381,47 KB

Share Result on Facebook

City

Geneva / Washington / DC / London / /

Company

Gilead Sciences Inc / Matrix Laboratories / FDC Ltd. / Merck / Dole / Aurobindo Pharma / Alkem Laboratories / Cipla / Ranbaxy Laboratories / /

Continent

Europe / /

Country

Switzerland / Rwanda / Zambia / Côte d'Ivoire / Haiti / Mozambique / South Africa / Namibia / Indonesia / Kenya / United States / Uganda / Vietnam / Guyana / Tanzania / Nigeria / Botswana / United Kingdom / China / Ethiopia / India / /

Currency

USD / /

/

Event

Patent Filing / Product Recall / Product Issues / M&A / /

Facility

Emory University / /

IndustryTerm

AIDS treatment / licensed suppliers / active pharmaceutical ingredients / treatment of HIV / manufacturing pharmaceuticals / patent law / treatment of AIDS / manufacturing / pharmaceutical products / standalone product / acceptable carrier / combination products / generic products / /

MedicalCondition

HIV / HBV / disease / Malaria / single disease / HBV infections / AIDS / HIV/AIDS / Tuberculosis / /

Organization

National Institute of Health / World Health Organization / US government / World Trade Organization / Federal Trade Commission / PEPFAR / Global Fund / United States government / Emory University / Congress / Federal Trade Commission Washington / DC / US federal government / TDF / FDA / Veterans Administration / /

Person

Raymond F. Schinazi / Bush / Woo-Baeg Chois / James Love / Dennis C. Liotta / /

/

Position

President / contractor / /

Product

Tamiflu / Efavirenz / Emtriva / patent oppositions / Truvada / Tenofivir / Viread / AIDS / Atripla / /

Technology

API / artificial intelligence / /

SocialTag